{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T06:06:05Z","timestamp":1792994765002,"version":"4.5.0"},"reference-count":158,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.jhep.2015.09.011","type":"journal-article","created":{"date-parts":[[2015,9,26]],"date-time":"2015-09-26T11:17:24Z","timestamp":1443266244000},"page":"486-504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":379,"title":["The importance of resistance to direct antiviral drugs in HCV infection in clinical practice"],"prefix":"10.1016","volume":"64","author":[{"given":"Christoph","family":"Sarrazin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2015.09.011_b0005","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.jhep.2015.09.011_b0010","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.26644","article-title":"Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35years after infection","volume":"59","author":"Wiese","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/jvh.12248","article-title":"The present and future disease burden of hepatitis C virus (HCV) infection with today\u2019s treatment paradigm","volume":"21","author":"Razavi","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.09.011_b0025","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3748\/wjg.v18.i12.1339","article-title":"Chronic hepatitis C: treat or wait? Medical decision making in clinical practice","volume":"18","author":"Niederau","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.09.011_b0030","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrmicro3046","article-title":"The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection","volume":"11","author":"Bartenschlager","year":"2013","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jhep.2015.09.011_b0035","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1473-3099(13)70059-8","article-title":"Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial","volume":"13","author":"Deterding","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2015.09.011_b0040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.12.010","article-title":"Immune responses to HCV and other hepatitis viruses","volume":"40","author":"Park","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jhep.2015.09.011_b0045","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2012.10.005","article-title":"Innate immunity and HCV","volume":"58","author":"Heim","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0050","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jcv.2009.09.029","article-title":"Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir","volume":"47","author":"Suzuki","year":"2010","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jhep.2015.09.011_b0055","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/S0168-8278(12)61106-4","article-title":"100% Svr in Il28b Cc patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the Prove2 trial","volume":"56","author":"Bronowicki","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0060","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27053","article-title":"All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naive patients with genotype 1 HCV infection","volume":"60","author":"Wyles","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0805","doi-asserted-by":"crossref","first-page":"30ra32","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"Rong","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2015.09.011_b0070","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1128\/JVI.02778-12","article-title":"Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients","volume":"87","author":"Dietz","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2015.09.011_b0075","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.01.003","article-title":"Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region","volume":"116","author":"Sarrazin","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2015.09.011_b0080","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jhep.2012.10.028","article-title":"Virologic response and characterisation of HCV genotype 2\u20136 in patients receiving TMC435 monotherapy (study TMC435-C202)","volume":"58","author":"Lenz","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0085","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.3851\/IMP1900","article-title":"NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1\u20135","volume":"16","author":"Vallet","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2015.09.011_b0090","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/jvh.12046","article-title":"Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes","volume":"20","author":"De Meyer","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.09.011_b0095","article-title":"Analysis of the durability of response and persistance of resistance associated variants during long term follow up after boceprevir plus pegylated interferon\/ribavirin therapy-3year analysis","volume":"58","author":"Howe","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0100","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/cit226","article-title":"Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials","volume":"57","author":"Sullivan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2015.09.011_b0105","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2014.11.032","article-title":"Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon\/ribavirin in Phase IIb\/III studies","volume":"62","author":"Lenz","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)30071-4","article-title":"Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir\/r, ombitasvir- and dasabuvir-based regimens","volume":"62","author":"Krishnan","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0115","article-title":"Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir","author":"Susser","year":"2011","journal-title":"J ClinVirol"},{"key":"10.1016\/j.jhep.2015.09.011_b0120","doi-asserted-by":"crossref","first-page":"S490","DOI":"10.1016\/S0168-8278(11)61244-0","article-title":"Long-term follow-up of chronic hepatitis C infected patients treated with telaprevir: evaluation of persistence of resistant variants by ultra-deep sequencing","volume":"54","author":"Thomas","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0125","article-title":"Baseline and post-baseline resistance analyses of phase 2\/3 studies of ledipasvir\/sofosbuvir +\/\u2212 RBV","volume":"60","author":"Sarrazin","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0130","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/hep.26388","article-title":"Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir","volume":"58","author":"McPhee","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)30073-8","article-title":"Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir","volume":"62","author":"Dvory-Sobol","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0140","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1128\/AAC.00998-15","article-title":"Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2015.09.011_b0145","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1128\/AAC.02386-13","article-title":"Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors","volume":"58","author":"Di Maio","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2015.09.011_b0150","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.12405","article-title":"Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy","author":"Hedskog","year":"2015","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.09.011_b0155","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","article-title":"Infrequent development of resistance in genotype 1\u20136 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials","volume":"59","author":"Svarovskaia","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2015.09.011_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)30012-X","article-title":"Retreatment of patients who failed 8 or 12weeks of ledipasvir\/sofosbuvir-based regimens with ledipasvir\/sofosbuvir for 24weeks","volume":"62","author":"Lawitz","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0165","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27375","article-title":"Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir","volume":"61","author":"Donaldson","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0170","article-title":"L159F and V321A sofosbuvir treatment-emergent HCV NS5B substitutions","volume":"60","author":"Svarovskaia","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0175","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.virol.2013.06.029","article-title":"Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies","volume":"444","author":"Barnard","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.jhep.2015.09.011_b0180","first-page":"1134a","article-title":"Pooled analysis of resistance in patients treated with ombitasvir\/ABT-450\/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials","volume":"60","author":"Krishnan","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0185","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","article-title":"HIV-1 antiretroviral resistance: scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.jhep.2015.09.011_b0190","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1055\/s-2004-813128","article-title":"Hepatitis C-virus \u2013 virus kinetics and resistance mechanisms","volume":"42","author":"Herrmann","year":"2004","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.jhep.2015.09.011_b0195","article-title":"Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b","author":"Vermehren","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.09.011_b0200","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1053\/j.gastro.2012.07.117","article-title":"Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy","volume":"143","author":"Lenz","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.09.011_b0205","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1128\/AAC.04911-14","article-title":"Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3\/4A protease inhibitor telaprevir","volume":"59","author":"Susser","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2015.09.011_b0210","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1053\/j.gastro.2014.05.010","article-title":"Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man","volume":"147","author":"Franco","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.09.011_b0215","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.antiviral.2008.11.002","article-title":"Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates","volume":"81","author":"Qi","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2015.09.011_b0220","article-title":"A phenotypic NS3-protease inhibitor resistance assay to characterize resistance-associated mutations in patients","volume":"22","author":"Rupp","year":"2015","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.09.011_b0225","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.09.011_b0230","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.09.011_b0235","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.09.011_b0240","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-0034-1371007","article-title":"New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development","volume":"34","author":"Pawlotsky","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2015.09.011_b0245","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0168-8278(12)60010-5","article-title":"Antiviral strategies in hepatitis C virus infection","volume":"56","author":"Sarrazin","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0250","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.09.011_b0255","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/hep.21781","article-title":"Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients","volume":"46","author":"Kieffer","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0260","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.09.011_b0265","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.09.011_b0270","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system","volume":"54","author":"Fridell","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2015.09.011_b0275","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.coviro.2012.08.004","article-title":"The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance","volume":"2","author":"Gotte","year":"2012","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.jhep.2015.09.011_b0280","doi-asserted-by":"crossref","first-page":"20509","DOI":"10.1073\/pnas.1105797108","article-title":"Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance","volume":"108","author":"Powdrill","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2015.09.011_b0285","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1053\/j.gastro.2007.01.041","article-title":"SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.09.011_b0290","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jhep.2011.12.033","article-title":"Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2\u20136: TMC435-C202, a phase IIa, open-label study","volume":"56","author":"Moreno","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0295","article-title":"Safety and antiviral activity of MK-5172, a next generation HCV NS3\/4A protease inhibitor with a broad HCV genotypic activity spectrum and potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients","volume":"54","author":"Petry","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0300","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00324-12","article-title":"MK-5172, a selective inhibitor of hepatitis C virus NS3\/4a protease with broad activity across genotypes and resistant variants","volume":"56","author":"Summa","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2015.09.011_b0305","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/hep.23192","article-title":"Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients","volume":"50","author":"Susser","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0310","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1053\/j.gastro.2009.10.033","article-title":"Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients","volume":"138","author":"Reesink","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.09.011_b0315","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1128\/AAC.04227-14","article-title":"In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3\/4A protease inhibitor ABT-450","volume":"59","author":"Pilot-Matias","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2015.09.011_b0320","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1128\/AAC.05854-11","article-title":"Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C","volume":"56","author":"Pasquinelli","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2015.09.011_b0325","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1128\/AAC.00308-12","article-title":"Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir","volume":"56","author":"McPhee","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2015.09.011_b0330","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2006.07.013","article-title":"Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study","volume":"131","author":"Reesink","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.09.011_b0335","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/cid\/ciu696","article-title":"Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon\/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection","volume":"59","author":"Howe","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2015.09.011_b0340","doi-asserted-by":"crossref","first-page":"e1025","DOI":"10.1053\/j.gastro.2014.07.019","article-title":"Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication","volume":"147","author":"Berger","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.09.011_b0345","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2015.09.011_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(12)61184-2","article-title":"Antiviral activity and resistance profile of the novel Hcv Ns5a inhibitor Gs-5885","volume":"56","author":"Cheng","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0355","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.04226-14","article-title":"In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2015.09.011_b0360","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/hep.24609","article-title":"Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1","volume":"54","author":"Nettles","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0365","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations","volume":"54","author":"Fridell","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0370","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2011.12.029","article-title":"A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C","volume":"57","author":"Lawitz","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0375","first-page":"438a","article-title":"MK-8742, a HCV NS5A inhibitor with a broad spectrum of HCV genotypic activity, demonstrates potent antiviral activity in genotype-1 and -3 HCV-infected patients","volume":"58","author":"Yeh","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0380","article-title":"A combination containing MK-5172 (HCV NS3 protease inhibitor) and MK-8742 (HCV NS5A inhibitor) demonstrates high barrier to resistance in HCV replicons","volume":"56","author":"Lahser","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0385","article-title":"8-week efficacy and safety of ABT-333 or ABT-972 with standard-of-care, following 3-day monotherapy in genotype 1 HCV-infected treatment-naive subjects","volume":"5","author":"Gaultier","year":"2011","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2015.09.011_b0390","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1128\/AAC.04619-14","article-title":"In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor","volume":"59","author":"Kati","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2015.09.011_b0395","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.09.011_b0400","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/jvh.12091","article-title":"All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear)","volume":"20","author":"Lawitz","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.09.011_b0405","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","volume":"56","author":"Lam","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2015.09.011_b0410","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.09.011_b0415","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.09.011_b0420","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.09.011_b0425","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.22549","article-title":"Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients","volume":"48","author":"Kuntzen","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0430","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/hep.22773","article-title":"Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy","volume":"49","author":"Gaudieri","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0435","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/591141","article-title":"Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects","volume":"198","author":"Bartels","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2015.09.011_b0440","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/infdis\/jiu340","article-title":"Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3\u20134A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study","volume":"210","author":"Dierynck","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2015.09.011_b0445","article-title":"Pooled clinical trial analyses of detectable baseline HCV NS3\/4A resistance associated variants on the efficacy of boceprevir plus pegylated interferon\/ribavirin therapy","volume":"58","author":"Howe","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0450","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/hep.25962","article-title":"Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial","volume":"56","author":"De Meyer","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0455","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3851\/IMP2632","article-title":"Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy","volume":"18","author":"Trimoulet","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2015.09.011_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)31021-7","article-title":"Analysis of NS3 protease resistance-associated variants and phenotypes for the prediction of treatment response to HCV triple therapy","volume":"62","author":"Dietz","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0465","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(14)71002-3","article-title":"Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial","volume":"15","author":"Reddy","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2015.09.011_b0470","article-title":"Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study","author":"Hezode","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2015.09.011_b0475","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1053\/j.gastro.2014.10.007","article-title":"Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection","volume":"148","author":"Dore","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.09.011_b0480","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.09.011_b0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134395","article-title":"Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients","author":"Dietz","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2015.09.011_b0490","doi-asserted-by":"crossref","first-page":"845A","DOI":"10.1016\/S0168-8278(13)60847-8","article-title":"Once-daily sofosbuvir plus ribavirin given 12 or 24 weeks in treatment-naive patients with HCV infection: the Quantum study","volume":"58","author":"Lalezari","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0495","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.09.011_b0500","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/hep.27361","article-title":"Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir\/ribavirin","volume":"61","author":"Hedskog","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0505","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"Lok","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.09.011_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(14)61059-X","article-title":"All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.09.011_b0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir\u2013elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2015.09.011_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)31088-6","article-title":"Efficacy and safety of grazoprevir\/elbasvir +\/- RBV for 12weeks in patients with HCV G1 or G4 infection who previously failed peginterferon\/RBV: C-EDGE treatment-experienced trial","volume":"62","author":"Kwo","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0530","doi-asserted-by":"crossref","first-page":"E360","DOI":"10.1111\/hepr.12316","article-title":"Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection","volume":"44","author":"Miura","year":"2014","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2015.09.011_b0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2015.03.033","article-title":"Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A","author":"Akamatsu","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0820","article-title":"Association between IFN-L3 (IL28B) and IFN-L4 genotypes and resistance-associated variants in HCV genotype 1 and 3 infected patients","author":"Peiffer","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0540","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)30168-9","article-title":"A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1","volume":"62","author":"Kwo","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0545","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.1016\/S0168-8278(15)30158-6","article-title":"A phase-3 open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2","volume":"62","author":"Lawitz","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0550","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.09.011_b0555","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.09.011_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)30976-4","article-title":"The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir\/sofosbuvvir +\/\u2212 RBV","volume":"62","author":"Sarrazin","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0565","doi-asserted-by":"crossref","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0570","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1001\/jama.2015.3860","article-title":"Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection","volume":"313","author":"Poordad","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2015.09.011_b0575","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.2015.3868","article-title":"Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis","volume":"313","author":"Muir","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2015.09.011_b0580","doi-asserted-by":"crossref","first-page":"634","DOI":"10.7326\/M14-1211","article-title":"Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study","volume":"161","author":"Osinusi","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2015.09.011_b0585","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(14)60010-6","article-title":"Successful retreatment with sofosbuvir-containing regimens for HCV genotype 2 or 3 infected patients who failed prior sofosbuvir plus ribavirin therapy","volume":"60","author":"Esteban","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0590","article-title":"Sofosbuvir in combination with PEG-IFN and ribavirin for 12 weeks provides high SVR rates in HCV infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the Lonestar-2 study","volume":"58","author":"Lawitz","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0810","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","author":"EASL","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0665","article-title":"Pooled clinical trial analyses of the effects of detectable baseline HCV NS3\/4a resistance-associated variants on the efficacy of boceprevir+pegylated interferon\/ribavirin therapy","volume":"58","author":"Howe","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0765","doi-asserted-by":"crossref","first-page":"e34372","DOI":"10.1371\/journal.pone.0034372","article-title":"Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials","volume":"7","author":"Kieffer","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2015.09.011_b0770","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)30056-8","article-title":"The phase 3 C-EDGE treatment-naive (TN) study of a 12-weeek oral regimen of grazoprevir (GZR, MK-5172)\/elbasvir (EBR, MK-8742) in patients with chronic HCV genotype (GT) 1, 4 or 6 infection","volume":"62","author":"Zeuzem","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0775","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1","author":"Wyles","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.09.011_b0780","article-title":"Daclatasvir in combination with sofosbuvir for HIV\/HCV coinfection: ALLY-2 study","volume":"23","author":"Wyles","year":"2015","journal-title":"Top Antivir Med"},{"key":"10.1016\/j.jhep.2015.09.011_b0785","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)30154-9","article-title":"Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: phase 3 Ally-1 study","volume":"62","author":"Poordad","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0790","unstructured":"European Medicines Agency. Assesment report Viekirax; 2015."},{"key":"10.1016\/j.jhep.2015.09.011_b0815","article-title":"Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection","author":"Zeuzem","year":"2015","journal-title":"J Hepatol."},{"key":"10.1016\/j.jhep.2015.09.011_b0600","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/JVI.02294-12","article-title":"Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment","volume":"87","author":"Bartels","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2015.09.011_b0605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofu078","article-title":"Clinical Implications of detectable baseline hepatitis C virus-genotype 1 NS3\/4A-protease variants on the efficacy of boceprevir combined with peginterferon\/ribavirin","volume":"1","author":"Howe","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jhep.2015.09.011_b0610","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2013.04.018","article-title":"Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a","volume":"99","author":"Palanisamy","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2015.09.011_b0620","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3851\/IMP2091","article-title":"Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor","volume":"17","author":"Plaza","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2015.09.011_b0625","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.3748\/wjg.v20.i11.2902","article-title":"Hepatitis C virus NS5A inhibitors and drug resistance mutations","volume":"20","author":"Nakamoto","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.09.011_b0635","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.12.020","article-title":"Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors","volume":"57","author":"Hernandez","year":"2013","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jhep.2015.09.011_b0640","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2014.10.001","article-title":"Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C Virus infection after liver transplantation","volume":"148","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.09.011_b0645","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/infdis\/jit562","article-title":"In vivo emergence of a novel mutant L159F\/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir","volume":"209","author":"Tong","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2015.09.011_b0650","doi-asserted-by":"crossref","first-page":"S498","DOI":"10.1016\/S0168-8278(14)61390-8","article-title":"Lack of impact of baseline resistance-associated variants (RAVs) on treatment outcome in the aviator study with ABT-450\/r, ABT-333 and ABT-267, +\/\u2212 ribavirin","volume":"60","author":"Krishnan","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0655","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1128\/AAC.01578-13","article-title":"In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir","volume":"57","author":"Jiang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2015.09.011_b0660","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","author":"Lenz","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2015.09.011_b0670","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1128\/AAC.02788-14","article-title":"Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity","volume":"58","author":"Wang","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2015.09.011_b0675","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1128\/JVI.00253-11","article-title":"Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052","volume":"85","author":"Fridell","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2015.09.011_b0680","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1021\/jm401398x","article-title":"Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A","volume":"57","author":"DeGoey","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.jhep.2015.09.011_b0685","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1128\/AAC.02193-12","article-title":"Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885","volume":"57","author":"Wong","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2015.09.011_b0690","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.1128\/AAC.01209-12","article-title":"Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir","volume":"56","author":"Pelosi","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2015.09.011_b0695","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1016\/S0168-8278(10)60764-7","article-title":"Resistance profile of Abt-333 and relationship to viral load decrease in patients treated in combination with peg-interferon and ribavirin for 28days","volume":"52","author":"Middleton","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0700","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct antiviral agents in patients with hepatitis C virus infection","volume":"138","author":"Sarrazin","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.09.011_b0705","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2013.02.018","article-title":"Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2\/3","volume":"59","author":"Silva","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.09.011_b0710","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/infdis\/jit274","article-title":"Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial","volume":"208","author":"Benhamou","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2015.09.011_b0715","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.05.046","article-title":"Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections","author":"Foster","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.09.011_b0720","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.antiviral.2007.11.010","article-title":"Characterization of resistance mutations against HCV ketoamide protease inhibitors","volume":"77","author":"Tong","year":"2008","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2015.09.011_b0725","unstructured":"Victrelis. Prescribing information. MSD; 2011."},{"key":"10.1016\/j.jhep.2015.09.011_b0730","first-page":"e814","article-title":"Differential sensitivity of 5\u2019UTR-NS5A recombinants of hepatitis C virus genotypes 1\u20136 to protease and NS5A inhibitors","volume":"146","author":"Li","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.09.011_b0735","doi-asserted-by":"crossref","first-page":"17508","DOI":"10.1074\/jbc.M313020200","article-title":"In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms","volume":"279","author":"Lin","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2015.09.011_b0740","unstructured":"Incivo. Prescribing information. Janssen; 2011."},{"key":"10.1016\/j.jhep.2015.09.011_b0745","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1128\/AAC.01186-12","article-title":"Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032)","volume":"56","author":"McPhee","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2015.09.011_b0750","article-title":"Virology analyses of HCV isolates from genotype 4 patients treated with simeprevir in combination with peginterferon\/ribavirin in the Phase III RESTORE study","volume":"60","author":"Fevery","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.09.011_b0755","first-page":"A108","article-title":"Phenotypic characterization of genotype 1 hepatitis C NS3 protease variants from clinical studies with simeprevir","volume":"19","author":"Verbinnen","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2015.09.011_b0760","unstructured":"Harvoni. Prescribing information. Gilead; 2014."},{"key":"10.1016\/j.jhep.2015.09.011_b0615","first-page":"1143a","article-title":"Evaluation of the resistance profile of ledipasvir, a nonstructural protein 5A inhibitor, in genotype 1 chronically infected HCV subjects treated with ledipasvir-containing regimens without sofosbuvir","volume":"60","author":"Kitrinos","year":"2014","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815006297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815006297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T04:41:32Z","timestamp":1565412092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827815006297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":158,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0168827815006297"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2015.09.011","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725812575.793515298","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2015.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}